Whittier Trust Co. Sells 1,425 Shares of DaVita Inc. (NYSE:DVA)

Whittier Trust Co. lowered its stake in DaVita Inc. (NYSE:DVA) by 22.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,039 shares of the company’s stock after selling 1,425 shares during the period. Whittier Trust Co.’s holdings in DaVita were worth $771,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kesler Norman & Wride LLC grew its stake in shares of DaVita by 15.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 5,643 shares of the company’s stock valued at $864,000 after purchasing an additional 769 shares during the period. Alps Advisors Inc. raised its holdings in shares of DaVita by 11.0% during the 1st quarter. Alps Advisors Inc. now owns 2,403 shares of the company’s stock worth $368,000 after acquiring an additional 239 shares in the last quarter. Crossmark Global Holdings Inc. raised its holdings in DaVita by 19.5% during the 1st quarter. Crossmark Global Holdings Inc. now owns 36,769 shares of the company’s stock valued at $5,625,000 after buying an additional 6,000 shares during the period. TD Private Client Wealth LLC grew its position in DaVita by 21.7% in the 1st quarter. TD Private Client Wealth LLC now owns 5,703 shares of the company’s stock valued at $872,000 after acquiring an additional 1,015 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its position in DaVita by 7.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company’s stock valued at $8,452,000 after acquiring an additional 4,048 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on DVA shares. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research report on Friday, April 25th. Truist Financial dropped their target price on DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a report on Monday, May 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $164.50.

DaVita Stock Performance

DVA opened at $143.35 on Friday. The stock has a market cap of $10.82 billion, a P/E ratio of 14.21, a P/E/G ratio of 0.98 and a beta of 1.11. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.25 and a quick ratio of 1.20. The stock’s 50 day simple moving average is $140.16 and its 200 day simple moving average is $148.63. DaVita Inc. has a 1-year low of $131.76 and a 1-year high of $179.60.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating the consensus estimate of $1.75 by $0.25. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.22 billion. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same period last year, the company posted $2.26 earnings per share. As a group, equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.